COMMUNIQUÉS West-GlobeNewswire

BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder
24/06/2019
Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites across the U.S. JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & [...]
Emerald Health Therapeutics Receives Cultivation License for New-Build Organic Cannabis Operation in British Columbia
24/06/2019
Organic facility consists of 156,000 sq. ft. in two greenhouses and potentially up to 24 acres of outdoor growing VANCOUVER, British Columbia, June 24, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“ [...]
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer
24/06/2019
Innovate intends to focus on non-dilutive sources of capital to further develop its pipeline, including out-licensing of (i) selective ex-US rights to INN-202 for celiac disease and (ii) Innovate’s earlier clinical [...]
Syneos Health Introduces FSP 360 – Next Evolution Model Provides Customers Broadest Range of Functional Service Provider Solutions
24/06/2019
Evolved Model Delivers Customized Solutions Across Entire Asset Portfolio MORRISVILLE, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions [...]
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
24/06/2019
HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the [...]
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
24/06/2019
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical [...]
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
24/06/2019
BUFFALO, N.Y., June 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Connectivity Wireless Strengthens Leadership Team
24/06/2019
ATLANTA, June 24, 2019 (GLOBE NEWSWIRE) -- Connectivity Wireless Solutions today celebrates the completion of its integration with Neutral Connect Networks. Since the acquisition of Connectivity Wireless was first [...]
MediPharm Labs Receives Permits and Ships First Medical Cannabis Concentrate to Australia
24/06/2019
TORONTO, June 24, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) , a leader in specialized, research-driven cannabis extraction and cannabinoid [...]
Exactus, Inc. Announces Appointment of Bobby Yampolsky to its Board of Directors
24/06/2019
DELRAY BEACH, Fla., June 24, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) (the “Company”), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, is pleased to announce the [...]
Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
24/06/2019
RANCHO CUCAMONGA, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, will be presenting at the BMO Prescriptions for Success [...]
Parallax Health Sciences Behavioral Health Division Announces the Development of Compass-ASD Version 2.0, its Data Driven Mobile Application
24/06/2019
SANTA MONICA, CA, June 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that [...]
Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices
24/06/2019
NEW YORK and MELBOURNE, Australia, June 24, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food [...]
R1 Showcases Latest Advancements in Automated Revenue Cycle Management at HFMA 2019 Annual Conference
24/06/2019
Builds largest digital workforce in healthcare revenue cycle with more than four million automated transactions annually to deliver superior financial results CHICAGO, June 24, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc . ( [...]
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
24/06/2019
Heidelberg, Germany, June 24, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the presentation of [...]
ALK submits registration application for tree SLIT-tablet in Canada
24/06/2019
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today announced that the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the [...]
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
24/06/2019
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS Milan, 24 June 2019 – Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, today reported that its strategy aimed [...]
Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
24/06/2019
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented [...]
BBS completes final manufacturing steps for CE marking
24/06/2019
BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the company’s ARTEBONE ® production line is ready for the audit required for CE marking. Following a successful audit, the certified [...]

Pages